LAWRENCE, Mass.--(BUSINESS WIRE)--Nexcelom Bioscience LLC, provider of innovative devices and instruments for cell-based assays in cancer research and drug discovery, today announced it continues to ...

Nexcelom Bioscience LLC has announced it has extended its product platform with the launch of the Cellometer Auto M10™ automatic cell counter. The Auto M10 maintains the user benefits of the ...

Ampersand Capital Partners has sold Nexcelom Bioscience to PerkinElmer for $260 million. Based in Lawrence, Massachusetts, Nexcelom is a provider of automated cell counting solutions. WELLESLEY, Mass.

Nexcelom Bioscience LLC, provider of innovative devices and instruments for cell-based assays in cancer research and drug discovery, today announced a major enhancement — the addition of ...

Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing Nexcelom is a leading, ...

The leading scientific social networking website and producer of educational virtual events and webinars.

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash. The transaction is ...